$XTNT

Xtant Medical Holdings, Inc. (XTNT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001453593 0001453593 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Becker’s reports six spine and orthopedic biologics developments in the first half of 2026. Ventris Medical received added patent coverage for its Backpack system. Xtant Medical launched the Trivium shaped bone graft. MTF Biologics and Kolosis BIO launched DBX Fiber. Medtronic’s Infuse bone graft received FDA premarket approval for one- and two-level transforaminal lumbar interbody spinal fusions. Kolosis Bio and MTF Biologics launched Summit Matrix. Tetrous received a U.S. patent for EnFix impl

Xtant Medical Holdings reported a Q1 2026 revenue of $20.9 million, a significant drop from $32.9 million in Q1 2025, primarily due to the sale of assets and non-recurring license revenue. Despite the decline, the company announced strategic moves like strengthening its balance sheet through asset sales, expanding into the hemostatics market, and integrating Dilon’s sales force, leading to an increased full-year 2026 revenue guidance of $101 million to $105 million.

Xtant Medical Holdings received an additional $10.7 million from Companion Spine, finalizing the total aggregate purchase price of $21.4 million for the sale of Coflex® assets and Paradigm OUS businesses. This payment includes $8.2 million for an unsecured promissory note and $2.2 million from working capital and other adjustments. Xtant Medical plans to use these funds to reduce long-term debt and increase cash liquidity, allowing them to focus on their higher-margin biologics business.